Due to the continuing COVID-19 pandemic, the 2021 AAN Annual Meeting was held in a fully virtual format from April 17-22.
Starting eptinezumab during a migraine attack results in rapid, sustained freedom from headache pain and most bothersome symptom (MBS), from two hours post-infusion, and decreased need for acute medication within 24 hours.1 It also delays the time to next migraine and provides meaningful improvements in patient-reported and migraine-related impact over the following four weeks.2 These …
Read more »Once daily atogepant 60 mg for migraine prevention was safe and well tolerated with no safety concerns identified, according to results of a multicentre open-label trial which included 739 adults with migraine with or without aura in the safety population (n=543 atogepant) (NCT03700320). Adverse events (AEs) were reported by 67% of patients treated with atogepant, …
Read more »Zavegepant 10 mg and 20 mg significantly improves freedom from pain and most bothersome symptom (photophobia, phonophobia, or nausea) two hours post-dose in patients with migraine, according to Phase 2/3 data on this intranasal, third-generation, small molecule CGRP antagonist (NCT03872453). In the 1581 patients analysed, approximately 14% of whom were taking preventive migraine medication, pain …
Read more »US migraine specialists are urging further research to fully understand the risk of hypertension in patients treated with erenumab and other anti-CGRP therapies. This follows an analysis of clinical trial and postmarketing data highlighting the limitations of current reports. Across pooled Phase 2/3, 12-week clinical trial data for erenumab (placebo [n = 1043], erenumab 70 …
Read more »A substantial proportion of patients who showed an inadequate response to fremanezumab after three months treatment in the HALO studies of episodic and chronic migraine experienced clinically meaningful reductions in migraine or headache days with longer treatment. Of 1,890 patients enrolled in the HALO long term study, 210 were inadequate initial responders – defined by …
Read more »Rimegepant 75 mg dosed up to once daily for up to 1 year showed favourable safety and tolerability in adults with migraine with cardiovascular (CV) risk factors, including adults with moderate to high CV risk.1 In adults with migraine and a history of triptan treatment failure, long-term dosing was also well tolerated. 2 These findings …
Read more »Ubrogepant offers comparable efficacy and safety in women with perimenstrual migraine (pmM) to that seen in other patients with migraine, according to data from a Phase 3, open-label, 52-week extension trial of adults with migraine randomised to usual care, ubrogepant 50mg, or ubrogepant 100mg. Of the 808 ubrogepant participants in the modified intent-to-treat population, 354 …
Read more »Low levels of efficacy ‘wearing off’ towards the end of galcanezumab treatment cycles have been reported from a post hoc analysis of data from the EVOLVE-1/2, REGAIN and CONQUER trials. In patients with high frequency episodic migraine, ‘wearing-off’ rates were comparable among placebo and galcanezumab 120 and 240 mg groups in EVOLVE-1/2 (7.0%, 5.8% and …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
